08Feb 2025
Zenocutuzumab Shows Promise for NRG1 Fusion-Positive Cancers

Zenocutuzumab Shows Promise for NRG1 Fusion-Positive Cancers

Zenocutuzumab is effective in treating NRG1 fusion-positive cancers. In a Phase 2 study, 30% of patients with advanced NRG1 fusion cancers responded to zenocutuzumab, with a median response duration of 11.1 months. Responses were observed in various tumors, especially non-small-cell lung cancer (29%) and pancreatic cancer (42%). Progression-free survival was 6.8 months, with mostly mild adverse events. Zenocutuzumab demonstrates the potential for treating this challenging cancer subtype.

  • #family health
  • #general medicine
  • #oncology

Like

Save

Share